Patient characteristics and utilization of breast cancer screening or diagnostic procedures prior to initiation of raloxifene, bisphosphonates and calcitonin

Foster, Stephan L.; Whangbo, Albert; Mitchell, Beth; Muram, David; Mershon, John L.; Kar, Rishi; Vedarajan, G

doi:10.1185/03007995.2010.515456

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results show that DM, rheumatologic diseases, and past hospitalization history were more common in the SERMs group than BP group, which is in contrast to the previous findings that SERM users had less comorbidities. 27 28 However, another study in Korean women with osteoporosis reported that the raloxifene group had a higher prevalence of rheumatologic and autoimmune diseases. 29 The reason was explained by the higher proportion of tertiary health care institutions among these patients, because raloxifene was more commonly prescribed by clinicians in the tertiary referral hospitals.…”

Section: Discussionmentioning

confidence: 99%

Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea

Park

Kim

et al. 2021

J Korean Med Sci

View full text Add to dashboard Cite

Background Selective estrogen receptor modulators (SERMs) were associated with an increased risk of venous thromboembolism (VTE) due to the estrogen effect. In this study, we investigated the effect of SERMs on VTE compared to bisphosphonates (BPs) using the Korean National Health Insurance claims database. Methods This was a retrospective cohort study. Women over 50 years old who were first prescribed BPs or SERMs for osteoporosis treatment in 2012 were included. The difference in VTE incidence between the SERMs and BP groups was compared. Both groups were followed up for VTE or PE occurrence, death, or until December 2016. The study population was analyzed by 3:1 matching according to age using a multivariate Cox model. Results The hazard ratio (HR) for VTE was 0.72 (95% confidence interval [CI], 0.40–1.28) in the SERMs group compared to BP group. Older age (60–69 vs. 50–59 years: HR, 3.77; 95% CI, 2.07–6.86 and 70–79 vs. 50–59 years: HR, 5.88; 95% CI, 3.14–11.02), major osteoporotic fracture (HR, 1.77; 95% CI, 1.16- 2.70), atrial fibrillation (HR, 3.31; 95% CI, 1.35–8.11), and estrogen replacement (HR, 3.40; 95% CI, 2.01–5.73) all increased VTE risk. In subgroup analysis of the SERMs group, past hospitalization (HR, 2.24; 95% CI, 1.02–4.92), estrogen replacement (HR, 5.75; 95% CI, 2.29–14.39), and glucocorticoid replacement (HR, 2.71; 95% CI, 1.05–7.0) increased VTE risk. Conclusion SERMs did not increase the risk of VTE compared to BPs in Koreans with osteoporosis. However, old age and estrogen replacement both increased VTE risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea

Park

Kim

et al. 2021

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…The higher proportion of osteoarthritis in the bisphosphonate group correlated well with the higher proportion of bisphosphonate from orthopedics clinicians in primary care institutions who also frequently treat osteoporosis and are more familiar with bisphosphonates than raloxifene. Likewise, gynecologists who are more aware of hormone replacement therapies and female organ specific cancers were more likely to prescribe raloxifene than bisphosphonates, as in Foster’s research [ 14 ]. However, the raloxifene group had a higher prevalence of rheumatologic and autoimmune diseases including rheumatoid arthritis, ankylosing spondylitis, and lupus, which is in contrast to the findings of a previous study [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…Previous drug utilization studies have shown that raloxifene users are younger and in a better overall health condition than bisphosphonate users [ 13 , 14 ]. However, these studies were conducted by only one research group by using the United States claims database, and there is a lack of published data, focusing on the Asian population, on the prescription pattern of the two drugs.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Prescribing Pattern of Bisphosphonate and Raloxifene in Korean Women with Osteoporosis: From a National Health Insurance Claims Database

et al. 2015

View full text Add to dashboard Cite

This study aimed to evaluate the differences of prescribing pattern between bisphosphonate and raloxifene users among Korean women with osteoporosis, focusing on the underlying conditions, concurrent medications, nature of healthcare utilization, and regional disparity. We used the Health Insurance Review and Assessment Service National Patients Sample database of the year 2010. Study subjects were defined as female osteoporosis patients aged over 50 years with both the diagnosis of osteoporosis and prescriptions of bisphosphonate or raloxifene. The frequency and the proportion of bisphosphonate and raloxifene were compared using chi-square test and the trend of the proportion using the Cochran–Armitage test. Medications were quantified as defined daily doses per 1,000 patients per day. The prescription pattern was visualized by using the Quantum Geographic Information Systems program. Of the 1,367,367 people who utilized medical services in 2010, the final number of study subjects was 26,881—26,032 (96.8%) bisphosphonate and 849 (3.2%) raloxifene recipients. Raloxifene users were younger than bisphosphonate users and were more frequently patients with a lipid disorder (16.0% vs. 22.1%, p-value < 0.0001), rheumatic disease (4.0% vs. 6.1%, p-value = 0.0024), hot flash (1.8% vs. 6.1%, p <0.0001), and coronary artery disease (1.2% vs. 2.8%, p< 0.0001). The proportion of raloxifene users was higher in tertiary care institutions (21.6% vs. 44.7%, p-value < 0.0001). A regional distribution showed that raloxifene use was higher in the Seoul metropolitan area. These differences in demographic and clinical profiles of each recipient may influence prescription decisions.

show abstract

Patient characteristics and utilization of breast cancer screening or diagnostic procedures prior to initiation of raloxifene, bisphosphonates and calcitonin

Cited by 2 publications

References 10 publications

Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea

Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea

Comparison of the Prescribing Pattern of Bisphosphonate and Raloxifene in Korean Women with Osteoporosis: From a National Health Insurance Claims Database

Contact Info

Product

Resources

About